<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110525</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00015</org_study_id>
    <secondary_id>2010-018864-18</secondary_id>
    <nct_id>NCT01110525</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives</brief_title>
  <official_title>A Phase I, Double-blind, Randomised, Placebo-controlled, Two-cycle Crossover, Drug-drug Interaction Study to Investigate the Effects of AZD1981 Tablets 400 mg Twice Daily on the PK and PD of Oral Contraceptives in Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether the treatment with AZD1981 will
      affect the metabolism of hormones included in oral contraceptives.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of of EE and LNG by analysis of the AUC and Css,max.</measure>
    <time_frame>PK sampling will be performed regularly during the study period of two months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on LH, FSH, SHBG, progesterone, and E2 during the menstrual cycle: Serum concentrations of LH, FSH, SHBG, progesterone and E2</measure>
    <time_frame>PD sampling will be done at the end of treatment period 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the combination: Adverse events, safety laboratory variables, pulse, blood pressure, electrocardiogram and physical examinations</measure>
    <time_frame>Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state PK of 1981 in combo with oral contraceptives AUCτ, Css,max, time to Cmax during a dosing interval (tmax ss);apparent plasma clearance (CLss/F) of AZD1981(tmax ss) of EE and LNG; Morning Ctrough values of EE and LNG will be measured.</measure>
    <time_frame>PK-sampling of AZD1981 wil be done at the end of treatment period 1 and 2.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Oral Contraceptives</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 + Oral contraceptive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Oral contraceptive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>4X100 mg per oral, twice daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neovletta 21/28</intervention_name>
    <description>Once daily with (21) or without (28) pause for bleeding.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo AZD1981</intervention_name>
    <description>4X100 mg per oral, twice daily for 28 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of childbearing potential

          -  Use of Neovletta or Neovletta 28 minimum 3 months prior to enrolment.

          -  Willing to use a highly effective method of birth control, ie, double barrier method
             contraception.

        Exclusion Criteria:

          -  Pregnancy and/or lactation or delivery/abortion within 6 months prior to
             randomisation.

          -  Any clinically significant disease or disorder.

          -  Any clinically relevant abnormal findings in physical examination.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva S Pettersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kühn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Phase I Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aslak Rautio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Hermelinen AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Oral contraceptives</keyword>
  <keyword>AZD 1981</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

